Loading stock data…
$1.79-0.05 (-2.72%)
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States.
Vyome Holdings, Inc. in the Healthcare sector is trading at $1.79 with a market capitalization of $14M. Wall Street consensus targets $8.83 (3 analysts), implying a +393.5% move over the next 12 months. The stock is currently near its 52-week low of $1.75, remaining 21.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26,955↓ | $31,591↓ | $36,551↑ | $34,627↓ | $49,954 |
| Gross Profit | $11,658↓ | $16,645↓ | $22,066↑ | $18,050↓ | $24,235 |
| Operating Income | -$862,566↑ | -$1.13M↑ | -$1.36M↓ | -$868,777↓ | -$324,189 |
| Net Income | -$685,556↑ | -$962,910↑ | -$1.06M↑ | -$8.60M↓ | -$308,760 |
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's ...